Skip to main content

Table 4 Comparison of cellular factors levels between the EBV positive and negative samples

From: Possible role of HPV/EBV coinfection in anoikis resistance and development in prostate cancer

Cellular Factors PCa group (a) vs control group (b) EBV-positive samples (c) vs EBV-negative samples (d) EBV-positive PCa (e) vs EBV-negative PCa (f) EBV-positive control (g) vs EBV-negative control (h) P* P+ P$ P^
NF-κB a: 19.4 ± 7.4
b: 9.5 ± 7
c: 18 ± 7.8
d: 12.7 ± 9
e: 22.4 ± 4.3
f: 15.4 ± 8.8
g: 10.9 ± 7
h: 7.1 ± 6.6
< 0.0001 0.006 0.004
1.45
ns
TNF-α a: 17 ± 7.4
b: 11.7 ± 6.7
c: 18 ± 5.5
d: 11.03 ± 8.1
e: 19.7 ± 5.7
f: 13.4 ± 7.9
g: 15.2 ± 4.1
h: 6 ± 6.4
0.002 < 0.0001 0.001
1.47
0.001
IL-1 a: 13 ± 5.7
b: 7.8 ± 5.3
c: 13.1 ± 5.3
d: 8.4 ± 6.1
e: 15 ± 4.6
f: 10.4 ± 6
g: 10 ± 4.8
h: 4.2 ± 4
0.0002 0.001 0.01
1.44
0.05
IL-6 a: 14.4 ± 6
b: 8.9 ± 6.6
c: 14.8 ± 5.8
d: 9 ± 6.6
e: 16.4 ± 5.5
f: 11.8 ± 5.9
g: 12.3 ± 5.5
h: 3.4 ± 3.9
0.0004 0.0003 0.02
1.3
0.004
IL-8 a: 12.62 ± 6.2
b: 5.68 ± 5.1
c: 10.4 ± 6.6
d: 9.7 ± 6.8
e: 12.7 ± 6.3
f: 12.4 ± 6.01
g: 6.7 ± 5.5
h: 4.1 ± 3.7
< 0.0001 ns ns ns
IL-11 a: 15.6 ± 8.3
b: 7.1 ± 6.2
c: 13.4 ± 8.6
d: 11.3 ± 8.5
e: 16.5 ± 8.3
f: 14.3 ± 8.2
g: 8.3 ± 6.4
h: 5.5 ± 5.2
< 0.0001 ns ns 0.049
IL-17 a: 9.8 ± 3.9
b: 4.3 ± 3.8
c: 8.2 ± 4.8
d: 7.4 ± 4.6
e: 10.2 ± 4.1
f: 9.4 ± 3.7
g: 4.9 ± 4.01
h: 3.3 ± 3.6
< 0.0001 ns ns ns
VEGF a: 38.64 ± 10.8
b: 13.7 ± 6.9
c: 33.5 ± 14
d: 27.9 ± 15.07
e: 40.8 ± 8.5
f: 32.8 ± 14.3
g: 23 ± 12.4
h: 14.05 ± 6.08
< 0.0001 0.03 0.01
1.2
0.02
TGF-β a: 15.2 ± 7.6
b: 7.5 ± 5.1
c: 13.5 ± 7.9
d: 10.9 ± 7.3
e: 16.4 ± 7.8
f: 13.6 ± 7.1
g: 8.7 ± 5.3
h: 5.4 ± 4.2
< 0.0001 ns ns 0.039
Rb a: 9.1 ± 5.7
b: 14.06 ± 6.4
c: 10.7 ± 6.2
d: 11.1 ± 6.8
e: 9.4 ± 6.1
f: 8.8 ± 5.4
g: 13 ± 5.8
h: 15.8 ± 7.3
0.0006 ns ns ns
P53 a: 10.4 ± 6.7
b: 13.9 ± 6.6
c: 10.8 ± 6.3
d: 13 ± 7.4
e: 10.1 ± 6.01
f: 10.9 ± 6.8
g: 11.9 ± 5.6
h: 17.3 ± 6.9
0.04 ns ns 0.02
ROS a: 10.2 ± 9.7
b: 6.09 ± 5.3
c: 8.9 ± 8.09
d: 9.07 ± 8.1
e: 9.8 ± 10.44
f: 9.6 ± 10.11
g: 5.2 ± 4.7
h: 7.5 ± 6.1
0.03 ns ns ns
RNS a: 11.8 ± 10.3
b: 5.2 ± 5.3
c: 9.6 ± 9.6
d: 9.2 ± 9.08
e: 12.52 ± 10.57
f: 10.9 ± 10.1
g: 5 ± 5.6
h: 5.3 ± 5.06
0.0002 ns ns ns
Survivin a: 17.8 ± 4.8
b: 9 ± 6.2
c: 16.3 ± 6.5
d: 12.3 ± 6.5
e: 19.9 ± 3.3
f: 15.1 ± 5.1
g: 10.4 ± 6.3
h: 6.5 ± 5.2
< 0.0001 0.031 0.02 ns
Bcl-2 a: 12.1 ± 4.2
b: 6.4 ± 4.5
c: 11.4 ± 5.4
d: 8.2 ± 4
e: 14.1 ± 3.9
f: 9.5 ± 3.5
g: 17.6 ± 0.5
h: 5.7 ± 3.9
0/0001 0.033 0.008 0.0005
CD44 a: 7.9 ± 5.1
b: 4.03 ± 2.4
c: 8.6 ± 4.7
d: 3.5 ± 2.6
e: 10.7 ± 4.7
f: 3.5 ± 1.6
g: 5.3 ± 2.2
h: 3.5 ± 3.5
0.0003 < 0.0001 < 0.0001 0.004
TWIST a: 10.2 ± 12.2
b: 6.4 ± 7.2
c: 8.6 ± 10.5
d: 9.2 ± 11.3
e: 9.9 ± 11.9
f: 10.7 ± 12.8
g: 6.5 ± 7.4
h: 6.2 ± 7.01
ns ns ns ns
E-cad a: 12.9 ± 8.4
b: 13.5 ± 5.6
c: 13.6 ± 7.7
d: 12.5 ± 7.3
e: 13.3 ± 8.6
f: 12.4 ± 8.3
g: 14.1 ± 6.2
h: 12.6 ± 4.7
ns ns ns ns
N-cad a: 10.7 ± 11.6
b: 5.8 ± 8.4
c: 8.6 ± 10.5
d: 9.5 ± 11.4
e: 10.2 ± 11.1
f: 11.4 ± 12.1
g: 6 ± 8.8
h: 5.6 ± 8.1
0.009 ns ns ns
PTPN13 a: 9.7 ± 5.9
b: 12.9 ± 6.6
c: 10.8 ± 6.4
d: 11.03 ± 6.3
e: 10.09 ± 6.22
f: 9.3 ± 5.7
g: 12 ± 6.7
h: 14.5 ± 6.3
0.03 ns ns ns
SLUG a: 2.1 ± 1.8
b: 1.1 ± 2.7
c: 1.8 ± 2.04
d: 1.9 ± 2.3
e: 2.05 ± 1.7
f: 2.6 ± 1.7
g: 1.6 ± 2.4
h: 0.2 ± 3.02
ns ns ns ns
  1. Geometric Mean ± Standard Deviation, *: comparison between group a versus group b, +: comparison between group c versus group d, $: comparison between group e versus group f, ^: $: comparison between group g versus group h, FDR correction for multiple comparisons by Benjamini-Hochberg method